NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 11:36 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Virpax Pharmaceuticals Stock (NASDAQ:VRPX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Virpax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2350-Day Range$0.21▼$4.2352-Week Range$0.13▼$84.75Volume5,400 shsAverage Volume201,138 shsMarket Capitalization$267,030.00P/E RatioN/ADividend YieldN/APrice Target$75.00Consensus RatingHold Company OverviewVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Read More… Virpax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreVRPX MarketRank™: Virpax Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingVirpax Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVirpax Pharmaceuticals has received no research coverage in the past 90 days.Read more about Virpax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioVirpax Pharmaceuticals has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VRPX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVirpax Pharmaceuticals does not currently pay a dividend.Dividend GrowthVirpax Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for VRPX. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for VRPX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Virpax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Virpax Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 32.23% of the stock of Virpax Pharmaceuticals is held by institutions.Read more about Virpax Pharmaceuticals' insider trading history. Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VRPX Stock News HeadlinesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…May 22, 2025 | Investors Alley (Ad)Virpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 19, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comSee More Headlines VRPX Stock Analysis - Frequently Asked Questions How have VRPX shares performed this year? Virpax Pharmaceuticals' stock was trading at $9.4975 at the beginning of 2025. Since then, VRPX stock has decreased by 97.7% and is now trading at $0.2150. View the best growth stocks for 2025 here. When did Virpax Pharmaceuticals' stock split? Virpax Pharmaceuticals shares reverse split on Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $15 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virpax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Daré Bioscience (DARE), Rallybio (RLYB), Mullen Automotive (MULN), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS). Company Calendar Today5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRPX CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$75.00 High Stock Price Target$75.00 Low Stock Price Target$75.00 Potential Upside/Downside+34,783.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,554.34% Return on Assets-338.29% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book0.13Miscellaneous Outstanding Shares1,242,000Free Float4,707,000Market Cap$267,030.00 OptionableNot Optionable Beta1.53 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:VRPX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.